<DOC>
	<DOCNO>NCT00632203</DOCNO>
	<brief_summary>The main objective study investigate whether administration maintenance temozolomide follow standard treatment could possibly prevent delay onset brain metastasis patient control non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Maintenance Temozolomide Versus Observation Stable Responding Stage III/IV Non-Small Cell Lung Cancer Patients ( Study P05146 )</brief_title>
	<detailed_description>This Phase 2 , open-label , randomize , multicenter study maintenance temozolomide versus observation subject stable respond stage III/IV NSCLC conduct conformance Good Clinical Practices . Subjects randomly assign study drug ( temozolomide ) observation arm . The study drug administer dose 75 mg/m^2 PO daily 21 consecutive day , follow 7-day rest period , progression maximum 6 cycle , whichever occur first . Subjects complete 6 cycle treatment follow incidence brain metastasis 2 year , progression .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Large Cell</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Adult subject ( age &gt; =18 year ) , either sex , race . Subjects must stage IV III pleural and/or pericardial effusion histologically confirm NSCLC . Subjects must complete 26 cycle standard systemic therapy , without radiation therapy , consist least 2 antitumor agent firstline treatment Stage III/IV disease , document complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) per Response Evaluation Criteria Solid Tumors ( RECIST ) . Response must confirm within 48 week complete firstline chemotherapy . Study treatment must begin within 12 week complete firstline chemotherapy . Female subject childbearing potential male subject female partner childbearing potential must agree use medically accept method contraception surgically sterilize prior Screening , receive study drug , 30 day stop study drug . Female subject childbearing potential must negative pregnancy test confirm prior dose study drug . Subjects must free clinically relevant disease ( stage III/IV NSCLC ) would , principal investigator and/or Sponsor 's opinion , interfere conduct study study evaluation . Subjects must able adhere dose visit schedule , agree report medication take , concomitant medication , adverse event ( AEs ) . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 . Clinical laboratory test ( complete blood count [ CBC ] , serum chemistry ) must obtain within 14 day prior randomization meet specify criterion . Brain metastasis document postchemotherapy magnetic resonance imaging ( MRI ) . Documented history brain metastasis . Subject receive one prior antitumor regimen Stage III/IV disease . `` Regimen '' refers single drug plan combination two antitumor therapy . Bevacizumab ( Avastin® ) part plan sequence therapy firstline platinumcontaining double regimen consider second regimen . Neoadjuvant treatment resectable subject consider second regimen . Subject use investigational product within 4 week prior enrollment . Subject currently receive immunotherapy chemotherapy , cytotoxic target therapy treatment active systemic disease . Bevacizumab ( Avastin® ) part prescribe standard firstline regimen allow . Female pregnant , intend become pregnant , study . Subject situation condition , opinion investigator , may interfere optimal participation study . Subject currently participate clinical study , exception observational longterm followup . Subject allergic , sensitivity , study drug excipients . Documented symptomatic , progressive new bone metastases follow firstline chemotherapy without radiation therapy ( biphosphonate use prophylaxis maintenance therapy allow ) . No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject diseasefree 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>